Aspire Biopharma Holdings, Inc. (ASBP)

Aspire Biopharma Holdings Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Sep 30, 2021
Cash & Equivalents	1.95	0	-	0.5	-
Cash & Short-Term Investments	1.95	0	-	0.5	-
Inventory	0.04	-	-	-	-
Other Current Assets	0.42	0.14	0.08	0.6	-
Total Current Assets	2.4	0.15	0.08	1.1	-
Long-Term Investments	-	-	19.9	299	-
Other Long-Term Assets	-	-	-	0.08	0.23
Total Assets	2.4	0.15	19.98	300.18	0.23
Accounts Payable	1.06	0.31	0.15	0.18	0
Accrued Expenses	0.27	-	-	-	0.01
Short-Term Debt	7.62	1.27	0.01	-	0.21
Other Current Liabilities	4.91	0.11	0.24	0.12	-
Total Current Liabilities	13.86	1.69	0.4	0.3	0.23
Other Long-Term Liabilities	0.01	0	-	10.81	-
Total Long-Term Liabilities	0.01	-	-	10.81	-
Total Liabilities	13.87	1.69	0.4	11.12	0.23
Common Stock	0	0	0	0	0
Additional Paid-in Capital	11.08	1.23	10.96	-	0.02
Retained Earnings	-22.55	-2.78	-11.29	-9.94	-0.02
Total Common Shareholders' Equity	-11.47	-1.54	-0.32	-9.94	0
Minority Interest	-	-	19.9	299	-
Shareholders' Equity	-11.47	-1.54	19.58	289.07	0
Total Liabilities & Equity	2.4	0.15	19.98	300.18	0.23
Total Debt	7.62	1.27	0.01	0	0.21
Net Cash (Debt)	-5.68	-1.26	-0.01	0.5	-0.21
Net Cash Per Share	-0.01	-0.00	-	12.95	-
Book Value	-11.47	-1.54	-0.32	-9.94	0
Book Value Per Share	-0.02	-0.00	-0.00	-258.89	-
Tangible Book Value	-11.47	-1.54	-0.32	-9.94	0
Tangible Book Value Per Share	-0.02	-0.00	-0.00	-258.89	-

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q